OKYO.US OKYO Pharma Limited

Healthcare Biotechnology USA Stocks
1.35 USD
Close of Nov 15, 2026
1.15 3.20
Market cap
USD 70.8M
P/E
-
P/B
5.70x
ROE
-206.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is OKYO.US undervalued?

Graham number

The Graham number of OKYO Pharma Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OKYO Pharma Limited fundamental analysis

No fundamental analysis for OKYO Pharma Limited yet.

OKYO Pharma Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OKYO Pharma Limited

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Full company profile